Skip to main content

Mercedes Arrue Gonzalo

I graduated in biology with a specialty in neurobiology in Madrid. After completing a master's degree in pharmacological research, I completed my PhD investigating the influence of diesel exhaust particles on ischemic stroke in the group of neurovascular diseases. Where I currently continue to develop my work.

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca
Mercedes Arrue Gonzalo

Mercedes Arrue Gonzalo

Mercedes Arrue Gonzalo

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I graduated in biology with a specialty in neurobiology in Madrid. After completing a master's degree in pharmacological research, I completed my PhD investigating the influence of diesel exhaust particles on ischemic stroke in the group of neurovascular diseases. Where I currently continue to develop my work.

PhD in Neuroscience (2018-2022)
Master in Pharmacological research (2017-2018)
Degree in Biology (2007-2013)

Projects

Advancing Parkinson's disease management: targeting autophagic-lysosomal dysfunction for innovative diagnostics and therapeutics

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Mercedes Arrúe Gonzalo, Silvia Enriquez Calzada, Jorge Hernández Vara, Pau Sarle Valles, Eddie Pradas Gracia, Maria Camprodon Gomez, Laura Castillo Ribelles, Clara Carnicer Cáceres, Jordi Riera Heredia, Pablo Castillo Sánchez
Funding agency: Instituto de Salud Carlos III
Funding: 265000
Reference: PI24/00062
Duration: 01/01/2025 - 31/12/2027

NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson's and Gaucher's disease

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Maria Camprodon Gomez, Pablo Castillo Sánchez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 42000
Reference: 2024 PROD 00073
Duration: 02/12/2024 - 01/06/2026

NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson´s and Gaucher's disease

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Jorge Hernández Vara, Maria Camprodon Gomez, Jordi Riera Heredia, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 24440
Reference: CI24-20222
Duration: 01/10/2024 - 30/09/2026

Malalties neurovasculars

IP: Anna Rosell Novel
Collaborators: Mercedes Arrúe Gonzalo, Joan Montaner Villalonga, Anna Penalba Morenilla, Maria Mar Hernandez Guillamon, Olga Maisterra Santos, Maria Pilar Delgado Martínez, Antonio Palasi Franco, Jesús Pizarro Gonzálvez, Miguel García Gabilondo, Nicolas Garcia Rodriguez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00656
Duration: 01/01/2022 - 30/06/2025

Related news

The initiative seeks to raise awareness of the disease and promote the well-being of those affected, while fostering empathy and scientific vocations among young people.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

Related professionals

Hugo Fernando Avalos  Bogado

Hugo Fernando Avalos Bogado

Predoctoral researcher
Rheumatology
Read more
Elba Agusti Rovira

Elba Agusti Rovira

Research technician
Donation and transplantation of organs, tissues and cells
Read more
Lucía Gutiérrez Ruiz

Lucía Gutiérrez Ruiz

Research technician
Clinical Neuroimmunology
Read more
Jon Esandi Jauregui

Jon Esandi Jauregui

Predoctoral researcher
Gene Therapy at Nervous System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.